Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers

The present study was aimed at developing and exploring the use of mannosylated dendritic architecture for the selective delivery of an anti-tuberculosis drug, rifampicin (RIF) to alveolar macrophages (AM). The mannosylated dendritic architecture was synthesized and characterized by using IR and NMR spectroscopy. RIF was efficiently loaded into mannosylated dendrimer using dissolution method. Various physicochemical and physiological parameters such as UV, SEM, DSC, drug loading, solubilization, pH dependent in-vitro release, hemolytic toxicity, phagocytic AM uptake and cytotoxicity concerning the mannosylated dendrimer were evaluated. RIF loaded mannosylated dendrimer reduced release rate of drug in pH 7.4, hemolytic toxicity and cytotoxicity; whereas enhanced drug release in pH 5.0 and AM uptake was observed. The present novel dendritic system displayed suitability in terms of biocompatibility and site-specific delivery of antitubercular drug RIF.

[1]  M. M. Villiers,et al.  Effect of polyamidoamine (PAMAM) dendrimers on the in vitro release of water-insoluble nifedipine from aqueous gels , 2005, AAPS PharmSciTech.

[2]  E. W. Meijer,et al.  Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[3]  Rajesh Pandey,et al.  Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. , 2003, The Journal of antimicrobial chemotherapy.

[4]  L. Heifets,et al.  Accumulation of Clarithromycin in Macrophages Infected With Mycobacterium avium , 1994, Pharmacotherapy.

[5]  Abhay Asthana,et al.  Poly(amidoamine) (PAMAM) dendritic nanostructures for controlled sitespecific delivery of acidic anti-inflammatory active ingredient , 2005, AAPS PharmSciTech.

[6]  N. Düzgüneş,et al.  Liposome-encapsulated antibiotics. , 2005, Methods in enzymology.

[7]  G. Soma,et al.  Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of rifampicin. , 2004, Colloids and surfaces. B, Biointerfaces.

[8]  N. K. Jain,et al.  Glycodendrimeric nanoparticulate carriers of primaquine phosphate for liver targeting. , 2005, International journal of pharmaceutics.

[9]  L. Piddock,et al.  Accumulation of rifampicin by Mycobacterium aurum, Mycobacterium smegmatis and Mycobacterium tuberculosis. , 2000, The Journal of antimicrobial chemotherapy.

[10]  N. Jain,et al.  PEGylated peptide-based dendritic nanoparticulate systems for delivery of artemether , 2005 .

[11]  B. G. Davis,et al.  Drug delivery systems based on sugar-macromolecule conjugates. , 2002, Current opinion in drug discovery & development.

[12]  E. W. Meijer,et al.  Poly(propylene imine) Dendrimers: Large‐Scale Synthesis by Hetereogeneously Catalyzed Hydrogenations , 1993 .

[13]  R. Gonzalez-Rothi,et al.  Effects of low-yield-cigarette smoke inhalation on rat lung macrophages. , 1986, Journal of toxicology and environmental health.

[14]  S. Jain,et al.  A PEGylated dendritic nanoparticulate carrier of fluorouracil. , 2003, International journal of pharmaceutics.

[15]  C. N. Reilley,et al.  Advances in analytical chemistry and instrumentation , 1960 .

[16]  Y. Lim,et al.  Polyplexes assembled with internally quaternized PAMAM-OH dendrimer and plasmid DNA have a neutral surface and gene delivery potency. , 2003, Bioconjugate chemistry.

[17]  D. Baldwin,et al.  Rifampicin concentrations in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum following a single 600 mg oral dose in patients undergoing fibre-optic bronchoscopy. , 2002, The Journal of antimicrobial chemotherapy.

[18]  J. McPherson,et al.  A comparison of the pharmacological properties of carbohydrate remodeled recombinant and placental-derived beta-glucocerebrosidase: implications for clinical efficacy in treatment of Gaucher disease. , 1999, Blood.

[19]  N. McKeown,et al.  The influence of surface modification on the cytotoxicity of PAMAM dendrimers. , 2003, International journal of pharmaceutics.

[20]  S Sridevi,et al.  Dendrimer-mediated transdermal delivery: enhanced bioavailability of indomethacin. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[21]  A. Dwivedi,et al.  Inhalable Microparticles Containing Drug Combinations to Target Alveolar Macrophages for Treatment of Pulmonary Tuberculosis , 2001, Pharmaceutical Research.

[22]  E. Meijer,et al.  Encapsulation of Guest Molecules into a Dendritic Box , 1994, Science.

[23]  J. Féger,et al.  Asialoglycoprotein receptor in human isolated hepatocytes from normal liver and its apparent increase in liver with histological alterations. , 1991, Journal of hepatology.

[24]  M. D. de Villiers,et al.  The effect of PAMAM dendrimer generation size and surface functional group on the aqueous solubility of nifedipine. , 2004, International journal of pharmaceutics.

[25]  J. Mitchell,et al.  A direct method for the formation of peptide and carbohydrate dendrimers. , 1999, Bioorganic & medicinal chemistry letters.

[26]  N. K. Jain,et al.  Evaluation of an aqueous injection of ketoprofen. , 1997, Die Pharmazie.

[27]  K. Kono,et al.  Water-soluble dendritic unimolecular micelles: their potential as drug delivery agents. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[28]  G. Gallo,et al.  Polymorphism of rifampicin. , 1977, Il Farmaco; edizione scientifica.

[29]  Chi‐Huey Wong,et al.  Emerging themes in medicinal glycoscience , 2000, Nature Biotechnology.

[30]  R. Duncan,et al.  Dendrimer biocompatibility and toxicity. , 2005, Advanced drug delivery reviews.

[31]  T. Higuchi,et al.  Phase solubility techniques , 1965 .

[32]  G. Newkome,et al.  Supramolecular chemistry of flexible, dendritic-based structures employing molecular recognition , 1996 .

[33]  B. G. Davis.  Recent developments in glycoconjugates , 2000 .

[34]  A. Gürsoy,et al.  Co-encapsulation of isoniazid and rifampicin in liposomes and characterization of liposomes by derivative spectroscopy. , 2004, International journal of pharmaceutics.

[35]  R. Banerjee,et al.  Effect of antitubercular drugs on dipalmitoylphosphatidylcholine monolayers: implications for drug loaded surfactants , 2005, Respiratory Physiology & Neurobiology.

[36]  M. Collins,et al.  Isolation of Rifampin-Resistant Mutants ofListeria monocytogenes and Their Characterization byrpoB Gene Sequencing, Temperature Sensitivity for Growth, and Interaction with an Epithelial Cell Line , 1999, Journal of Clinical Microbiology.